ENDRA Life Sciences Reports Q1 Loss, Confirms Nasdaq Delisting Notice, Discloses Material Weakness & Critical Liquidity

summarizeSummary

ENDRA Life Sciences reported an increased Q1 net loss, confirmed a Nasdaq delisting notice due to insufficient stockholders' equity, and disclosed a material weakness in internal controls, all while facing critical liquidity issues and a going concern warning.

check_boxKey Events

• Going Concern Warning & Critical Liquidity

  The company reported a cash balance of $356,462 and negative working capital of $(298,774) as of March 31, 2026. It explicitly states 'substantial doubt about the Company's ability to continue as going concern' due to insufficient revenue to cover operating costs and the need for additional financing.

• Nasdaq Delisting Notice Confirmed

  ENDRA Life Sciences received a Nasdaq delisting notice on April 20, 2026, for failing to meet the minimum stockholders' equity requirement ($2.26 million as of December 31, 2025, further decreasing to $1.79 million by March 31, 2026). The company has requested a hearing to appeal this decision.

• Material Weakness in Internal Controls

  Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, identifying a material weakness due to 'insufficient personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting.'

• Increased Net Loss & Operating Cash Burn

  The net loss for Q1 2026 increased to $1.31 million from $1.04 million in Q1 2025. Net cash used in operating activities for the quarter was $1.12 million, indicating a high burn rate relative to current cash reserves.

auto_awesomeAnalysis

This quarterly report highlights ENDRA Life Sciences' severe financial distress, confirming a Nasdaq delisting notice and disclosing a material weakness in internal controls. The company's cash balance is critically low, and it explicitly states substantial doubt about its ability to continue as a going concern. The reliance on digital asset sales and an At-The-Market program for liquidity underscores the urgent need for capital, while the internal control weakness raises concerns about financial reporting reliability. These factors collectively present a highly negative outlook and significant risk to investors.